Hypofractionated radiotherapy for glioblastoma: correlation with prognostic factors and survival outcomes.

IF 1.7 Q4 ONCOLOGY

Reports of Practical Oncology and Radiotherapy Pub Date : 2025-10-31 eCollection Date: 2025-01-01 DOI:10.5603/rpor.108278

Dimcho Georgiev, Svetlana Bilyukova, Cyril Kounin

{"title":"Hypofractionated radiotherapy for glioblastoma: correlation with prognostic factors and survival outcomes.","authors":"Dimcho Georgiev, Svetlana Bilyukova, Cyril Kounin","doi":"10.5603/rpor.108278","DOIUrl":null,"url":null,"abstract":"Background: The purpose was to evaluate the efficacy of hypofractionated radiotherapy (HFRT) followed by conventional fractionated radiotherapy (CFRT) in glioblastoma multiforme (GBM) patients and identify prognostic factors.Materials and methods: We conducted a retrospective analysis of 120 GBM patients treated postoperatively between 2010 and 2017 with HFRT (30 Gy in 3 Gy fractions) followed by CFRT (24 Gy in 2 Gy fractions), for a total dose of 60 Gy. All patients received concurrent and adjuvant temozolomide (TMZ).Results: Median age was 62.5 years. Median overall survival (OS) was 11.3 months; 1-, 2-, and 3-year survival rates were 43.3%, 16.1%, and 4.6%, respectively. Full dose completion correlated with improved OS (12.2 vs. 7.3 vs. 4.6 months for ≥ 100%, 90-99%, and < 70% dose realization, respectively). Age ≤ 63 years and gros tumor volume (GTV) ≤ 44.5 cm3 were associated with significantly better survival. Gender had no significant impact.Conclusions: HFRT followed by CFRT with TMZ is an effective alternative to standard CFRT in patients with subtotal or partial resection. Age and tumor volume are independent prognostic factors for overall survival.","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"30 5","pages":"683-689"},"PeriodicalIF":1.7000,"publicationDate":"2025-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12772950/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reports of Practical Oncology and Radiotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5603/rpor.108278","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The purpose was to evaluate the efficacy of hypofractionated radiotherapy (HFRT) followed by conventional fractionated radiotherapy (CFRT) in glioblastoma multiforme (GBM) patients and identify prognostic factors.

Materials and methods: We conducted a retrospective analysis of 120 GBM patients treated postoperatively between 2010 and 2017 with HFRT (30 Gy in 3 Gy fractions) followed by CFRT (24 Gy in 2 Gy fractions), for a total dose of 60 Gy. All patients received concurrent and adjuvant temozolomide (TMZ).

Results: Median age was 62.5 years. Median overall survival (OS) was 11.3 months; 1-, 2-, and 3-year survival rates were 43.3%, 16.1%, and 4.6%, respectively. Full dose completion correlated with improved OS (12.2 vs. 7.3 vs. 4.6 months for ≥ 100%, 90-99%, and < 70% dose realization, respectively). Age ≤ 63 years and gros tumor volume (GTV) ≤ 44.5 cm³ were associated with significantly better survival. Gender had no significant impact.

Conclusions: HFRT followed by CFRT with TMZ is an effective alternative to standard CFRT in patients with subtotal or partial resection. Age and tumor volume are independent prognostic factors for overall survival.

Abstract Image

查看原文本刊更多论文

胶质母细胞瘤的低分割放疗：与预后因素和生存结果的关系。

背景：目的是评估低分割放疗（HFRT）后常规分割放疗（CFRT）治疗多形性胶质母细胞瘤（GBM）患者的疗效，并确定预后因素。材料和方法：我们回顾性分析了2010年至2017年期间接受HFRT （30 Gy， 3 Gy分次）和CFRT （24 Gy， 2 Gy分次）治疗的120例GBM患者，总剂量为60 Gy。所有患者同时和辅助使用替莫唑胺（TMZ）。结果：中位年龄为62.5岁。中位总生存期（OS）为11.3个月；1年、2年和3年生存率分别为43.3%、16.1%和4.6%。全剂量完成与OS改善相关（对于≥100%、90-99%和< 70%的剂量实现，分别为12.2、7.3和4.6个月）。年龄≤63岁、肿瘤体积(GTV)≤44.5 cm3与生存率显著提高相关。性别没有显著影响。结论：对于次全或部分切除的患者，HFRT和CFRT联合TMZ是标准CFRT的有效替代方案。年龄和肿瘤体积是影响总生存率的独立预后因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Reports of Practical Oncology and Radiotherapy Multiple-

CiteScore

2.80

自引率

8.30%

发文量

115

审稿时长

16 weeks

期刊介绍： Reports of Practical Oncology and Radiotherapy is an interdisciplinary bimonthly journal, publishing original contributions in clinical oncology and radiotherapy, as well as in radiotherapy physics, techniques and radiotherapy equipment. Reports of Practical Oncology and Radiotherapy is a journal of the Polish Society of Radiation Oncology, the Czech Society of Radiation Oncology, the Hungarian Society for Radiation Oncology, the Slovenian Society for Radiotherapy and Oncology, the Polish Study Group of Head and Neck Cancer, the Guild of Bulgarian Radiotherapists and the Greater Poland Cancer Centre, affiliated with the Spanish Society of Radiotherapy and Oncology, the Italian Association of Radiotherapy and the Portuguese Society of Radiotherapy - Oncology.